Moderna (MRNA) Reports Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Moderna's (MRNA) COVID-19 Vaccine Manufactured in Korea by Samsung Granted Marketing Authorization from Ministry of Food and Drug Safety of Korea

Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Spikevax®, Moderna's COVID-19 vaccine (mRNA-1273) manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.

This marketing authorization obtained by Moderna Korea officially allows the Moderna's COVID-19 vaccine manufactured at Samsung Biologics' local pharmaceutical production facilities to be distributed within Korea and... More

Moderna (MRNA) Declines 7% Pre-Open Following Interim Phase 1 Data for mRNA Flu Vaccine and Program Update

Moderna (NASDAQ: MRNA) Declines 7% Pre-Open Following Interim Phase 1 Data for mRNA Flu Vaccine and Program Update

Stocks with Implied Volatility Movement

Moderna (NASDAQ: MRNA) volatility index movement decreasing vs. 30D HV

Moderna (MRNA) Will Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host a live conference call and webcast on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010 tomorrow, Friday, December 10, 2021 at 8:00... More

CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg

CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg

BioNTech (BNTX) and Pfizer (PFE) Beneficiaries From Lower Omicron Vaccine Efficacy - SVB Leerink

SVB Leerink analyst Daina Graybosch reiterated Market Perform ratings on BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) after the companies confirmed that the protection conferred by vaccination with Comirnaty is 20-fold lower against Omicron compared to wild type... More

Moderna (MRNA) on Watch as Pfizer/BioNTech SE Three Dose Regimen Neutralizes Omicron

Moderna (NASDAQ: MRNA) shares are on watch as rivals Pfizer/BioNTech SE said three of their vaccine doses neutralize the Omicron variant. Both use similar mRNA technology, so it could be assumed that Moderna's jab has the same impact. Shares of MRNA are down 2% in pre-open trading.